Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Collaboration with GSK

Published: Wednesday, March 14, 2012
Last Updated: Tuesday, March 13, 2012
Bookmark and Share
Three year biomarker collaboration in the field of fibrosis research.

Epistem plc, has announced a three year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research.

The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp™ technology to facilitate building an in depth understanding of the disease.

RNA-Amp™ is highly sensitive amplification technology which is able to provide gene expression information from small tissue samples and low of numbers of cells e.g. those obtained from the bulb of cells at the base of a single hair follicle, as well as laser captured micro dissected (LCM) samples.

Epistem is now the preferred partner of choice for a range of pharmaceutical companies providing gene expression biomarker information to support drug development programmes.

In addition to its amplification technology, Epistem brings its well respected cell and molecular biology expertise to the collaboration.

Epistem’s broad platform allows protein and gene expression biomarkers to be identified in important disease pathways at an early stage of pre-clinical validation for translation through to later stage clinical validation and patient stratification.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem Announces Collaboration With Sanofi-Aventis
3 year collaboration to provide discovery through to clinical biomarker support to oncology programmes of sanofi-aventis and its affiliates.
Monday, March 21, 2011
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!